Insider Buying: Agilon Health (NYSE:AGL) Director Buys 81,000 Shares of Stock

Agilon Health, Inc. (NYSE:AGL) Director John William Wulf purchased 81,000 shares of the business’s stock in a transaction on Wednesday, November 12th. The stock was purchased at an average cost of $0.63 per share, for a total transaction of $51,030.00. Following the acquisition, the director owned 365,857 shares in the company, valued at approximately $230,489.91. The trade was a 28.44% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Agilon Health Price Performance

AGL stock traded down $0.03 during midday trading on Friday, hitting $0.84. The stock had a trading volume of 6,296,853 shares, compared to its average volume of 6,084,399. The business has a 50-day moving average of $0.77 and a two-hundred day moving average of $1.04. Agilon Health, Inc. has a 52-week low of $0.51 and a 52-week high of $6.08.

Agilon Health (NYSE:AGL) last issued its earnings results on Tuesday, November 4th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.09). Agilon Health had a negative return on equity of 75.92% and a negative net margin of 5.24%.The firm had revenue of $1.44 billion during the quarter, compared to the consensus estimate of $1.43 billion. Research analysts expect that Agilon Health, Inc. will post -0.59 EPS for the current fiscal year.

Analyst Ratings Changes

AGL has been the subject of several research analyst reports. Royal Bank Of Canada upgraded Agilon Health from a “hold” rating to a “moderate buy” rating in a report on Wednesday, December 3rd. BTIG Research reaffirmed a “neutral” rating on shares of Agilon Health in a research report on Friday, December 12th. Weiss Ratings restated a “sell (e+)” rating on shares of Agilon Health in a research note on Wednesday, January 21st. Wells Fargo & Company cut their target price on shares of Agilon Health from $1.50 to $1.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. Finally, Barclays lowered their price objective on Agilon Health from $1.50 to $1.00 and set an “underweight” rating on the stock in a report on Thursday, November 6th. Four equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $2.71.

Institutional Investors Weigh In On Agilon Health

Institutional investors have recently modified their holdings of the company. CenterBook Partners LP lifted its position in shares of Agilon Health by 492.4% during the 3rd quarter. CenterBook Partners LP now owns 11,428,027 shares of the company’s stock worth $11,771,000 after buying an additional 9,499,012 shares during the last quarter. Geode Capital Management LLC boosted its position in Agilon Health by 2.6% during the second quarter. Geode Capital Management LLC now owns 7,156,466 shares of the company’s stock worth $16,462,000 after purchasing an additional 178,477 shares in the last quarter. Bank of America Corp DE lifted its stake in Agilon Health by 41.3% in the 3rd quarter. Bank of America Corp DE now owns 5,414,614 shares of the company’s stock valued at $5,577,000 after buying an additional 1,581,284 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in Agilon Health by 6.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 5,060,333 shares of the company’s stock valued at $21,911,000 after acquiring an additional 311,158 shares during the last quarter. Finally, UBS Group AG increased its position in Agilon Health by 250.7% during the fourth quarter. UBS Group AG now owns 3,395,366 shares of the company’s stock worth $2,339,000 after purchasing an additional 2,427,136 shares during the last quarter.

Key Agilon Health News

Here are the key news stories impacting Agilon Health this week:

• Positive Sentiment: Agilon director John William Wulf bought 81,000 AGL shares (avg. $0.63) in November, increasing his stake by ~28%—an insider purchase investors often view as a sign of confidence. Insider Form 4
• Neutral Sentiment: Brokerage consensus remains lukewarm: recent coverage shows an average recommendation of “Hold,” suggesting analysts are cautious but not uniformly bearish. Analyst Consensus
• Negative Sentiment: Bronstein, Gewirtz & Grossman filed/urged investors to act in a class action alleging investor harm against Agilon and certain officers—adds to legal exposure and headline risk. Bronstein, Gewirtz & Grossman filing
• Negative Sentiment: Faruqi & Faruqi says it is investigating claims on behalf of Agilon investors and is soliciting potential class members—more counsel activity increases likelihood of consolidated litigation and potential discovery/settlement costs. Faruqi & Faruqi notice
• Negative Sentiment: Multiple other plaintiff firms (Rosen, Levi & Korsinsky, Bernstein Liebhard, Pomerantz, The Gross Law Firm) have filed or issued shareholder alerts reminding investors of lead‑plaintiff deadlines—this sustained outreach keeps Agilon in the legal headlines and may pressure the stock. Rosen Law Firm notice Levi & Korsinsky notice Bernstein Liebhard notice Pomerantz notice The Gross Law Firm notice

About Agilon Health

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.